The purpose of the study is to determine the link between CYP11B2 (-344ТС) and ATIIR1 (A1166C) polymorphisms and their combinations with anxiety and depressive disorders (ADD) in patients with ST-elevation myocardial infarction (STEMI). Materials and methods. 85 patients with STEMI were examined, 68 (80%) men and 17 (20%) women, with the average age (58,94±10,16) years old. We used the questionnaire of HADS (Heart Anxiety and Depression Scale) and the Tailor questionnaire for objectification of existing alarming and depressive disorders which are risk factors of a myocardial infarction. Testing of patients allowed allocating two groups: the first one was with normal or limit implication of alarm it made up 48 patients, and the second group had 37 patients with the increased level. Allele polymorphism Т344С of CYP11B2 and A1166C of ATIIR1 gene were determined by polymerase chain reaction in real time. Statistics was obtained thanks to software package Statistica 8.0 (Stat SoftInc, USA), Microsoft Office Exсel 2003. ADD were diagnosed with the help of Tailor questionnaire and Heart Anxiety and depression Scale (HADS). All the patients were divided in two groups – with ADD and without them. Results and discussion. Observed and estimated frequencies of investigated polymorphisms were in tune with Hardi-Weinberg equilibrium (P>0,05). Relative risk of STEMI in the presence of ADD is associated with TT-genotype of CYP11B2 gene (-Т344С polymorphism), OR 0,33, 95% CI [0,13-0,91], Р=0,05, Т-allele, OR 1,94, 95% CI [0,04-3,56], Р=0,03, combination of 1166АА-344ТТ-variants, Р=0,049. 344С-allele of CYP11B2 gene can be considered as protective factor: OR 0,52, 95% CI [0,28-0,96], Р=0,03. Conclusions. 344T-allele and 344TT-polymorphism of CYP11B2 gene is associated with higher relative risk of STEMI in the presence of ADD. In patients with STEMI and ADD more often appears the combination of 1166АА-344ТТ-polymorphous variants of ATIIR1 and CYP11B2 genes. We found no associations between polymorphous variants of ATIIR1 gene and ADD in patients with STEMI.

Keywords: STEMI, anxiety and depressive disorders, CYP11B2 (-344ТС) and ATIIR1 (A1166C) polymorphisms

Full text: PDF (Ukr) 205K

1. Kokorin VA, Volov NA, Dudareva AV, i dr. Neirohumor alnie narusheniia i metody ih korrektsii u bolnych, perenesshich infarct miocarda. Rossiiski Kardiologicheski Zhurnal. 2009; 1 (75): 62-8. [Russian]
2. Kovalenko VM. Stres i chvoroby systemy krovoobigu: posobnyk pid red Kovalenka VM, Kornatskogo VM. Natsionalny naukovy centr “Instytut kardiologii im VMStrazheska. Kyiv, 2015. 52 s. [Ukrainian]
3. Tseluiko VI, Yakovleva LM, Popova KI. Faktory shco vplyvayut na perebig infarctu miokarda u hvorych na ishemichnu hvorobu sertsya. Liky Ukrainy. 2013; 3-4 (16-17): 19-23. [Ukrainian]
4. Zhebel VM, Starzhynska OL, Gefter YuO ta spivavt. Genotyp receptora do angiotensynu II 1 typu yak factor vplyvu na strukturu ta funktsiiu miocarda u chvorych na hypertonichnu hvorobu riznoi tyazhkosti. Arterialnaia Hypertensiia. 2009; 1 (3): 24-9. [Ukrainian]
5. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2012; 33: 2569–619. https://www.ncbi.nlm.nih.gov/pubmed/22922416. https://doi.org/10.1093/eurheartj/ehs215
6. Gomes-Sanchez E, Gomes-Sanchez CE. The multifaceted mineralocorticoid receptor. ComprPhisiol. 2014; 4 (3): 965-94. https://doi.org/10.1002/cphy.c130044
7. Graeff FG. Anxiety, panic and the hypothalamic-pituitary-adrenal axis. Rev Bras Psiquiatr. 2007; 29 (1): 53-6. http://dx.doi.org/10.1590/S1516-44462007000500002
8. Guimond MO, Gallo-Payet N. The Angiotensin II type 2 receptor in brain functions: an Update. International Journal of Hypertension. 2012; Article ID 351758, 18 pages. https://doi.org/10.1155/2012/351758
9. Hara M, Sakata Y, Sato H. Genetic Factors in Myocardial Infarction. Rinsho Byori. 2013; 61 (2): 176-83. https://www.ncbi.nlm.nih.gov/pubmed/23672096
10. Hengstenberg C, Holmer SR, Mayer B, et al. Evaluation of the aldosterone synthase (CYP112B) gene polymorphism in patients with myocardial infarction. Hypertension. 2000; 35: 704-9. https://doi.org/10.1161/01.HYP.35.3.704
11. Kruzliak P, Kovacova G, Pechanova O, et al. Association between Angiotensin II type I receptor polymorphism and sudden cardiac death in myocardial infarction. Dis Markers. 2013; 35 (5): 287-93. https://doi.org/10.1155/2013/731609
12. Kubzanski LD, Adler GK. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev. 2010; 34 (1): 80-6. https://www.ncbi.nlm.nih.gov/pubmed/19631234. https://www.ncbi.nlm.nih.gov/pmc/articles/3099453. https://doi.org/10.1016/j.neubiorev.2009.07.005
13. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review 69.and recommendations: a scientific statement for the American Heart Association. Circulation. 2014; 129: 1350-69. https://www.ncbi.nlm.nih.gov/pubmed/24566200. https://doi.org/10.1161/CIR.0000000000000019
14. May HT, Horne BD, Knight S, Knowlton KU, Bair TL, Lappé DL, Le VT, Muhlestein JB. The association of depression at any time to the risk of death following coronary artery disease diagnosis. European Heart Journal – Quality of Care and Clinical Outcomes. 2017; 3: 296-302. https://www.ncbi.nlm.nih.gov/pubmed/28950317. https://doi.org/10.1093/ehjqcco/qcx017
15. Murck H, Held K, Ziegenbein M, Künzel H, Koch K, Steiger A. The rennin-angiotensin-aldosteron system in patients with depression compared with controls – a sleep endocrine study. BMC Psychiatry. 2003; 3: 15. https://doi.org/10.1186/1471-244X-3-15
16. Preuss M, Kônig IR, Thompson JR, Erdmann J, Absher D, Assimes TL, Blankenberg S, Boerwinkle E, Chen L, et al. Design of the Coronary Disease Genome-Wide Replication And Meta-Analyses (CARDIoGRAM) Study. Circ Cardiovasc Genet. 2010; 3 (5): 475-83. https://www.ncbi.nlm.nih.gov/pubmed/20923989. https://www.ncbi.nlm.nih.gov/pmc/articles/3070269. https://doi.org/10.1161/CIRCGENETICS.109.899443
17. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J. 2007; 54 (3): 359-70. https://www.ncbi.nlm.nih.gov/pubmed/17409575. https://doi.org/10.1507/endocrj.KR-80
18. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-conrol study. Lancet. 2004; 364 (9438): 937-52. https://doi.org/10.1016/S0140-6736(04)17018-9
19. Zennaro MC, Rickard AJ, Boulkroun S, et al. Genetics of mineralocorticoid excess: an update for clinicians. European Journal of Endocrinology. 2013; 169: 15-25. https://doi.org/10.1530/EJE-12-0813